Nektar Therapeutics (NKTR) Liabilities and Shareholders Equity (2010 - 2026)

Nektar Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $763.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 197.87% year-over-year to $763.3 million; the TTM figure through Mar 2026 stood at $1.6 billion (up 28.16% YoY), while the FY2025 annual figure was $280.4 million, down 7.72% from the prior year.
• Liabilities and Shareholders Equity was $763.3 million for Q1 2026 at Nektar Therapeutics, up from $280.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.0 billion in Q1 2022 to a low of $207.5 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $496.1 million across 5 years, with a median of $398.0 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity sank 45.15% in 2023, then jumped 197.87% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $710.6 million in 2022, then slumped by 43.99% to $398.0 million in 2023, then decreased by 23.66% to $303.8 million in 2024, then decreased by 7.72% to $280.4 million in 2025, then jumped by 172.2% to $763.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $763.3 million (Q1 2026), $280.4 million (Q4 2025), and $301.3 million (Q3 2025), per Business Quant data.